-
Regulus Therapeutics (RGLS) Bullish Stance Reiterated at BMO Capital Following EASL Abstract for RG-101
-
BMO Capital Reiterates Bullish Stance on Regulus Therapeutics (RGLS) as Incremental Efficacy of RG101 Could Support New Option in HCV
-
Regulus Therapeutics (RGLS) Gains on Clinical Map Update; BMO Capital Sees Multiple Opportunities to Realize Value
-
Regulus Therapeutics (RGLS) Price Target Raised to $34 at BMO; Could Attract Interest from Big Pharma, Says Analyst
-
Regulus Therapeutics (RGLS) 5.29M Offering Prices at $17/Share
-
Regulus Therapeutics (RGLS) Reports $80M Common Stock Offering
-
Regulus Therapeutics (RGLS) Announces $80M Common Stock Offering
-
Streetinsider.com's Hot Lunchtime Reads 10/22: (JNJ) (BIIB) (OCN) (FL) (RGLS)
-
Regulus (RGLS) Impressive RG101 Results Could Transform HCV Treatment, BMO Capital Says
-
Regulus Therapeutics (RGLS) Prices 4.5M Shares at $9.50
-
BMO Capital Starts Regulus Therapeutics (RGLS) at Outperform
-
Regulus Therapeutics (RGLS) IPO Closes 5% Higher

